Public biotech with avexitide (GLP-1 antagonist) Phase 3 LUCIDITY for hypoglycemia/hyperinsulinism; AMX0035 in Wolfram syndrome; AMX0114 ALS; AMX0318; team ~300
No detailed funding rounds available.
Total known funding: